eyeforpharma The Marketing Disruption Summit

eyeforpharma2 - 3 October 2019, Philadelphia, USA.
It's 2019 and Marketing is changing. Your customers' expectations have shifted to ‘one-click’. They expect more, they’re used to intuitive consumer interactions, and now they're looking at pharma.

Providing the seamless, personalized experience you've been dreaming about has never seemed closer. But marketers can't do it alone.

The Marketing Disruption Summit attendance is already ahead of expectations, with groups of industry leaders from across Marketing, Strategy, Data and IT already booked to delve deep into specifics with talks, workshops and case studies from top pharma, and equip themselves to be the key changemakers at home.

On current predictions, tickets will sell out this year. Ensure you have a place reserved at the only event where pharma marketing, data & IT change makers redefine customer interaction.

Reach out like never before

With Industry Leading Speakers carefully selected to cover every aspect of the back and front-end customer cycle, and an agenda designed to provide solutions to all the collaborative problems holding back your customer engagement:

Including:

  • Martina Flammer SVP customer value, Boehringer Ingelheim
  • Krishna Cheriath Chief Data Officer BMS
  • Alessandra Almeida Snr Director, Global Head of Master Data Management, Sanofi
  • Ignacio Quiles lara exec director global marketing and commercial ops, Abbvie
  • Ramon Vega head of global pharma marketing IT, Merck
  • Renaud Sermondade Head of insights and analytics, Sanofi

Unite to exceed changing customer demands

Marketers: Understand the technical capabilities within your business, build results-based strategies, and unite teams behind your vision.

Data: Communicate your capabilities and gain vital authority in strategic conversations.

Technology: Show stakeholders what your internal teams can do and inspire new strategies with innovation.

Together: Build cross functional strategies to revolutionize, personalize and redefine customer interaction.

World Pharma News readers can benefit from an exclusive discount, just use the code WPN300 to save $300 when you register here

For further information, please visit:
https://www.eyeforpharma.com/marketingusa/

About eyeforpharma

Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...